Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | glutaminase 2 | 0.0317 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0128 | 0.2911 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0128 | 0.2911 | 0.2911 |
Schistosoma mansoni | glutaminase | 0.0317 | 1 | 1 |
Mycobacterium ulcerans | glutaminase | 0.0317 | 1 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0128 | 0.2911 | 0.2911 |
Trichomonas vaginalis | glutaminase, putative | 0.0317 | 1 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0128 | 0.2911 | 0.2911 |
Echinococcus granulosus | tar DNA binding protein | 0.0128 | 0.2911 | 0.5 |
Brugia malayi | RNA binding protein | 0.0128 | 0.2911 | 0.2911 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0128 | 0.2911 | 0.2911 |
Brugia malayi | TAR-binding protein | 0.0128 | 0.2911 | 0.2911 |
Loa Loa (eye worm) | glutaminase | 0.0317 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.